| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Molecular Targets, and Chemical Biology |
1 Inserm, U466, Toulouse, France; 2 CNRS, Institut de Pharmacologie et de Biologie Structurale, UMR 5089, Toulouse, France; 3 Université Paul Sabatier, Faculté de Médecine, H
pital Rangueil, Service d'Urologie et de Transplantation Rénale, Toulouse, France; and 4 Université Paul Sabatier, Faculté de Médecine, H
pital Rangueil, Service d'Anatomie et Cytologie Pathologiques, Toulouse, France
Requests for reprints: Olivier Cuvillier, Institut National de la Santé et de la Recherche Médicale U466, BP 84225, 31432 Toulouse, France. Phone: 33-5-61-32-20-60; Fax: 33-5-61-32-20-84; E-mail: olivier.cuvillier{at}toulouse.inserm.fr.
Systemic chemotherapy was considered of modest efficacy in prostate cancer until the recent introduction of taxanes. We took advantage of the known differential effect of camptothecin and docetaxel on human PC-3 and LNCaP prostate cancer cells to determine their effect on sphingosine kinase-1 (SphK1) activity and subsequent ceramide/sphingosine 1-phosphate (S1P) balance in relation with cell survival. In vitro, docetaxel and camptothecin induced strong inhibition of SphK1 and elevation of the ceramide/S1P ratio only in cell lines sensitive to these drugs. SphK1 overexpression in both cell lines impaired the efficacy of chemotherapy by decreasing the ceramide/S1P ratio. Alternatively, silencing SphK1 by RNA interference or pharmacologic inhibition induced apoptosis coupled with ceramide elevation and loss of S1P. The differential effect of both chemotherapeutics was confirmed in an orthotopic PC-3/green fluorescent protein model established in nude mice. Docetaxel induced a stronger SphK1 inhibition and ceramide/S1P ratio elevation than camptothecin. This was accompanied by a smaller tumor volume and the reduced occurrence and number of metastases. SphK1-overexpressing PC-3 cells implanted in animals developed remarkably larger tumors and resistance to docetaxel treatment. These results provide the first in vivo demonstration of SphK1 as a sensor of chemotherapy. (Cancer Res 2005; 65(24): 11667-75)
This article has been cited by other articles:
![]() |
R. K. Barr, H. E. Lynn, P. A. B. Moretti, Y. Khew-Goodall, and S. M. Pitson Deactivation of Sphingosine Kinase 1 by Protein Phosphatase 2A J. Biol. Chem., December 12, 2008; 283(50): 34994 - 35002. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Li, H.-Y. Guan, L.-Y. Gong, L.-B. Song, N. Zhang, J. Wu, J. Yuan, Y.-J. Zheng, Z.-S. Huang, and M. Li Clinical Significance of Sphingosine Kinase-1 Expression in Human Astrocytomas Progression and Overall Patient Survival Clin. Cancer Res., November 1, 2008; 14(21): 6996 - 7003. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Ader, L. Brizuela, P. Bouquerel, B. Malavaud, and O. Cuvillier Sphingosine Kinase 1: A New Modulator of Hypoxia Inducible Factor 1{alpha} during Hypoxia in Human Cancer Cells Cancer Res., October 15, 2008; 68(20): 8635 - 8642. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Ye Lysophospholipid signaling in the function and pathology of the reproductive system Hum. Reprod. Update, September 1, 2008; 14(5): 519 - 536. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Pchejetski, N. Doumerc, M. Golzio, M. Naymark, J. Teissie, T. Kohama, J. Waxman, B. Malavaud, and O. Cuvillier Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models Mol. Cancer Ther., July 1, 2008; 7(7): 1836 - 1845. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Takabe, S. W. Paugh, S. Milstien, and S. Spiegel "Inside-Out" Signaling of Sphingosine-1-Phosphate: Therapeutic Targets Pharmacol. Rev., June 1, 2008; 60(2): 181 - 195. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mimeault, P. P. Mehta, R. Hauke, and S. K. Batra Functions of Normal and Malignant Prostatic Stem/Progenitor Cells in Tissue Regeneration and Cancer Progression and Novel Targeting Therapies Endocr. Rev., April 1, 2008; 29(2): 234 - 252. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gomez-Brouchet, D. Pchejetski, L. Brizuela, V. Garcia, M.-F. Altie, M.-L. Maddelein, M.-B. Delisle, and O. Cuvillier Critical Role for Sphingosine Kinase-1 in Regulating Survival of Neuroblastoma Cells Exposed to Amyloid-beta Peptide Mol. Pharmacol., August 1, 2007; 72(2): 341 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Baran, A. Salas, C. E. Senkal, U. Gunduz, J. Bielawski, L. M. Obeid, and B. Ogretmen Alterations of Ceramide/Sphingosine 1-Phosphate Rheostat Involved in the Regulation of Resistance to Imatinib-induced Apoptosis in K562 Human Chronic Myeloid Leukemia Cells J. Biol. Chem., April 13, 2007; 282(15): 10922 - 10934. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. W. Howard, M.-T. Ling, C. W. Chua, H. W. Cheung, X. Wang, and Y. C. Wong Garlic-Derived S-allylmercaptocysteine Is a Novel In vivo Antimetastatic Agent for Androgen-Independent Prostate Cancer Clin. Cancer Res., March 15, 2007; 13(6): 1847 - 1856. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mimeault, S. L. Johansson, G. Vankatraman, E. Moore, J.-P. Henichart, P. Depreux, M.-F. Lin, and S. K. Batra Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells Mol. Cancer Ther., March 1, 2007; 6(3): 967 - 978. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Maceyka, S. Milstien, and S. Spiegel Shooting the Messenger: Oxidative Stress Regulates Sphingosine-1-Phosphate Circ. Res., January 5, 2007; 100(1): 7 - 9. [Full Text] [PDF] |
||||
![]() |
D. Pchejetski, O. Kunduzova, A. Dayon, D. Calise, M.-H. Seguelas, N. Leducq, I. Seif, A. Parini, and O. Cuvillier Oxidative Stress-Dependent Sphingosine Kinase-1 Inhibition Mediates Monoamine Oxidase A-Associated Cardiac Cell Apoptosis Circ. Res., January 5, 2007; 100(1): 41 - 49. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Murph, T. Tanaka, S. Liu, and G. B. Mills Of Spiders and Crabs: The Emergence of Lysophospholipids and Their Metabolic Pathways as Targets for Therapy in Cancer. Clin. Cancer Res., November 15, 2006; 12(22): 6598 - 6602. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |